The TGFβ-SMAD3 pathway inhibits IL-1α induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration

[1]  S. Pothula,et al.  Key role of pancreatic stellate cells in pancreatic cancer. , 2016, Cancer letters.

[2]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[3]  D. Tuveson,et al.  Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.

[4]  A. Carrato,et al.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs , 2015, Journal of Gastrointestinal Cancer.

[5]  Maria Fichera,et al.  Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. , 2015, The New England journal of medicine.

[6]  E. Witkowski,et al.  Outcomes in operative management of pancreatic cancer , 2014, Journal of surgical oncology.

[7]  L. Howells,et al.  Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. , 2014, European journal of cancer.

[8]  Kunio Matsumoto,et al.  Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. , 2014, Experimental cell research.

[9]  Daniel Öhlund,et al.  Fibroblast heterogeneity in the cancer wound , 2014, The Journal of experimental medicine.

[10]  M. Korc,et al.  Pancreatic cancer stroma: friend or foe? , 2014, Cancer cell.

[11]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[12]  D. Sandnes,et al.  Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma , 2014, BMC Cancer.

[13]  P. Moynagh.  The roles of Pellino E3 ubiquitin ligases in immunity , 2014, Nature Reviews Immunology.

[14]  E. Raymond,et al.  Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas , 2013, Oncotarget.

[15]  L. Bojmar,et al.  IL-1α Expression in Pancreatic Ductal Adenocarcinoma Affects the Tumor Cell Migration and Is Regulated by the p38MAPK Signaling Pathway , 2013, PloS one.

[16]  C. Logsdon,et al.  Roles for KRAS in pancreatic tumor development and progression. , 2013, Gastroenterology.

[17]  K. Olive,et al.  Pancreatic cancer: why is it so hard to treat? , 2013, Therapeutic advances in gastroenterology.

[18]  Y. Miao,et al.  Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma , 2013, International journal of cancer.

[19]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[20]  A. Hezel,et al.  TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. , 2012, Cancer research.

[21]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[22]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[23]  Jian Ye,et al.  Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction , 2012, BMC Bioinformatics.

[24]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[25]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[26]  Ruiying Zhao,et al.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[27]  H. Druid,et al.  Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. , 2011, Neoplasia.

[28]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[29]  H. Funahashi,et al.  Cancer cell‐derived IL‐1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells , 2010, Journal of surgical oncology.

[30]  S. Park,et al.  Smad7 and Smad6 bind to discrete regions of Pellino-1 via their MH2 domains to mediate TGF-beta1-induced negative regulation of IL-1R/TLR signaling. , 2010, Biochemical and biophysical research communications.

[31]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[32]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[33]  Hiroki Takahashi,et al.  Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. , 2009, The Journal of surgical research.

[34]  Douglas B. Evans,et al.  Secreted Interleukin-1α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-κB , 2009, Molecular Cancer Research.

[35]  C. Hill,et al.  Tgf-beta superfamily signaling in embryonic development and homeostasis. , 2009, Developmental cell.

[36]  L. O’Neill,et al.  The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.

[37]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[38]  G. Tortora,et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.

[39]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[40]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[41]  M. Omary,et al.  The pancreatic stellate cell: a star on the rise in pancreatic diseases. , 2007, The Journal of clinical investigation.

[42]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[43]  S. Wahl,et al.  TGF‐β: a mobile purveyor of immune privilege , 2006 .

[44]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[45]  Robert Jaster,et al.  Molecular regulation of pancreatic stellate cell function , 2004, Molecular Cancer.

[46]  J S Wilson,et al.  Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells , 2004, Pancreas.

[47]  C. Thorn,et al.  TGF‐β down‐regulates IL‐1α‐induced TLR2 expression in murine hepatocytes , 2004, Journal of leukocyte biology.

[48]  P. Chiao,et al.  Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1α in Induction of Constitutive NF-κB Activation in Pancreatic Cancer Cells* , 2004, Journal of Biological Chemistry.

[49]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[50]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[51]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[52]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[53]  R. Schmid,et al.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans. , 1998, Gastroenterology.

[54]  T. Shimosegawa,et al.  Expression of Transforming Growth Factor β1 (TGFβ1) and Its Receptors in Pancreatic Duct Cell Carcinoma and in Chronic Pancreatitis , 1998 .

[55]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[56]  C. Dubois,et al.  Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action , 1990, The Journal of experimental medicine.

[57]  S. Dower,et al.  T-cell interleukin 1 receptor cDNA expressed in Chinese hamster ovary cells regulates functional responses to interleukin 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Zhiwei Wang,et al.  Pancreatic cancer: understanding and overcoming chemoresistance , 2011, Nature Reviews Gastroenterology &Hepatology.

[59]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[60]  S. Wahl,et al.  TGF-beta: a mobile purveyor of immune privilege. , 2006, Immunological reviews.

[61]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.

[62]  P. Chiao,et al.  Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. , 2004, The Journal of biological chemistry.

[63]  C. Thorn,et al.  TGF-beta down-regulates IL-1alpha-induced TLR2 expression in murine hepatocytes. , 2004, Journal of leukocyte biology.

[64]  J. Ringel,et al.  Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. , 2001, Cancer research.

[65]  J. Ringel,et al.  Transforming Growth Factor-β1 Induces Desmoplasia in an Experimental Model of Human Pancreatic Carcinoma , 2001 .

[66]  H. Friess,et al.  The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. , 1999, Oncogene.

[67]  K. Satoh,et al.  Expression of transforming growth factor beta1 (TGFbeta1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis. , 1998, Pancreas.